The reevaluation of "forgotten" antibiotics can identify new therapeutic options against extensively drug-resistant Gram-negative pathogens. We sought to investigate isepamicin in this regard. We retrospectively evaluated the antimicrobial susceptibility to isepamicin of Enterobacteriaceae sp. isolates from unique patients, collected at the microbiological laboratory of the University Hospital of Heraklion, Crete, Greece, from 2004 to 2009. Susceptibility testing was done with the automated Vitek 2 system. The breakpoints for susceptibility to isepamicin, tigecycline, and other antibiotics were those proposed by the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM), the FDA, and the CLSI, respectively. A total of 6,296 isolates were studied, including primarily 3,401 (54.0%) Escherichia coli, 1,040 (16.5%) Klebsiella pneumoniae, 590 (9.4%) Proteus mirabilis, and 460 (7.3%) Enterobacter sp. isolates. Excluding the species with intrinsic resistance to each antibiotic, antimicrobial susceptibility was highest for colistin ( . The antimicrobial susceptibility of the 1,040 K. pneumoniae isolates was highest for isepamicin (95.3%), followed by colistin (89.3%) and meropenem (63.0%). Regarding resistant K. pneumoniae isolates, susceptibility to isepamicin was observed for 91.1% of the 392, 87.7% of the 375, and 85.6% of the 111 isolates that were nonsusceptible to the carbapenems, all other aminoglycosides, and colistin, respectively. Isepamicin exhibited high in vitro activity against almost all of the Enterobacteriaceae species. It could particularly serve as a last-resort therapeutic option for carbapenem-resistant K. pneumoniae in our region, where it is endemic, as it does not show considerable cross-resistance with other aminoglycosides.
I
n the era of increasing antimicrobial resistance, multidrug-resistant Enterobacteriaceae, particularly Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. that produce carbapenemases, extended-spectrum ␤-lactamases, or AmpC ␤-lactamases, are of major concern worldwide (4). Carbapenem-resistant K. pneumoniae isolates are typically resistant to all antibiotics except for colistin, tigecycline, gentamicin, and fosfomycin, but resistance to these agents, particularly to colistin, is increasing (16) .
Although several antimicrobial agents targeting Gram-positive cocci have rather recently been approved for clinical use, this is not the case for Gram-negative bacilli (2, 23) . The reevaluation of older but "forgotten" antimicrobials can lead to the identification of agents that have retained activity against contemporary problem pathogens, according to the example of colistin and fosfomycin. These agents could then serve as a last-resort treatment for infections with extensively resistant Gram-negative pathogens (14, 15) .
Members of the aminoglycoside class of antibiotics can have antimicrobial activity against certain multidrug-resistant Gramnegative pathogens (9) . Isepamicin, a derivative of gentamicin B, is one of the latest aminoglycosides to have been introduced in clinical practice (i.e., in 1988 in Japan) (31) . It has been available in only a limited number of countries (including Japan, South Korea, China, and other Asian countries as well as certain European countries like Belgium and Italy) (27, 38) . The susceptibility of Gram-negative bacterial isolates to isepamicin can be higher than that to amikacin (12) . In a selection of 65 of carbapenem-resistant Enterobacteriaceae strains, other than NDM-1 producers, 63 were found to be susceptible to isepamicin (27) .
We sought to evaluate the in vitro activity of isepamicin against contemporary Enterobacteriaceae clinical isolates in Crete, Greece, a region with a generally high prevalence of antimicrobial resistance among Gram-negative pathogens.
MATERIALS AND METHODS
Study design and setting. We retrospectively analyzed all the clinical Enterobacteriaceae sp. isolates that were collected at the microbiological laboratory of the University Hospital of Heraklion (Heraklion, Crete, Greece) from February 2004 to September 2009 and for which data for susceptibility to isepamicin were available. When multiple isolates of the same species were identified in the same patient more than once within 6 months, we included only the first isolate per patient. The University Hospital of Heraklion is a 680-bed, tertiary care, general hospital serving a population of around 650,000 persons.
Specimen processing and culture were done according to routine laboratory methods. The identification of bacterial species was performed by the use of standard biochemical methods, the API 20E system and the Vitek 2 automated system (bioMérieux SA, Marcy l'Etoile, France). The Vitek 2 system was also used for antimicrobial susceptibility testing. The Clinical and Laboratory Standards Institute (CLSI) breakpoints (6a) were used for the interpretation of susceptibility to all antimicrobial agents except for isepamicin and tigecycline. For isepamicin, the breakpoints proposed in 2010 by the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM) were used: susceptibility was defined by an MIC less than or equal to 8 mg/liter, and resistance was defined by an MIC higher than 16 mg/liter (3). For tigecycline, the U.S. Food and Drug Administration (FDA) guidelines for Enterobacteriaceae were used. The study isolates were not routinely tested against chloramphenicol, fosfomycin, and tigecycline, because these antibiotics were either not available or not considered for clinical use for most of the study period.
E. coli ATCC 25922 was tested as a quality control strain for susceptibility to isepamicin with the Vitek 2 system once weekly throughout the study period. To evaluate the accuracy of isepamicin susceptibility testing with the Vitek 2 system, 10 isepamicin-susceptible and 10 isepamicinresistant, randomly selected isolates were retested by using the disk diffusion method (3). Thirty-microgram isepamicin disks (Bio-Rad SA, Marnes La Coquette, France) were used, and the disk zone diameters were interpreted according to CA-SFM criteria (3) .
Definitions and data analysis. We assessed the percentages of susceptible, intermediately susceptible, and resistant isolates for each of the major Enterobacteriaceae sp. isolates studied and against all isolates. We did not take into consideration the automated susceptibility testing data for antibiotics against species that are considered to have intrinsic resistance, according to the European Committee on Antimicrobial Susceptibility Testing (26) .
We specifically focused on subsets of isolates exhibiting clinically relevant resistance patterns, such as resistance to carbapenems, aminoglycosides, or colistin, and isolates with an extensively drug-resistant (XDR) or pandrug-resistant (PDR) phenotype. XDR isolates were those that were resistant to all but one or two classes of antimicrobial agents among those available during the study period, while PDR isolates were those isolates that were resistant to all classes of antimicrobial agents (11) . To adjust for the fact that susceptibility to fosfomycin and tigecycline was not routinely tested, the XDR and PDR isolates that were characterized according to the definitions mentioned above are referred to as possible XDR (p-XDR) and possible PDR (p-PDR) isolates, respectively (28) . Differences in susceptibility were compared by using the chi-square test.
RESULTS

Characteristics of the studied isolates.
A total of 12,796 clinical Enterobacteriaceae sp. isolates were collected at the microbiological laboratory of the University Hospital of Heraklion during the 6-year study period. For 7,589 (59.3%) unselected isolates, data for susceptibility to isepamicin were available. After the exclusion of multiple isolates of the same species per patient, 6,296 clinical isolates were finally included in our study. The most common pathogens were E. coli (3, Table 1 .
Almost two-thirds of the patients who provided the clinical isolates analyzed in this study were inpatients (4,211/6,296 patients [66.9%]), and the remaining one-third were outpatients. Of the inpatients, 1,308 (31%) patients were hospitalized in medical departments, 747 (18%) patients were hospitalized in hematology or oncology departments, 1,045 (25%) patients were hospitalized in surgical departments, 547 (13%) patients were hospitalized in pediatric departments, 494 (12%) patients were hospitalized in intensive care units (ICU), and the remaining 70 (2%) patients were hospitalized in renal replacement units. The types of culture specimens from which the studied pathogens were most frequently isolated included urine (3, Antimicrobial susceptibility. Detailed data on the susceptibility of the studied Enterobacteriaceae sp. isolates to all tested antibiotics are presented in Table 2 . Among all the isolates studied (excluding for each antibiotic those with intrinsic resistance), antimicrobial susceptibility was highest for colistin (5 
All isolates except intrinsically resistant b
All isolates (n ϭ 6,296) c [98.9%]). Figure 1 shows the temporal trend in the susceptibility of K. pneumoniae isolates to isepamicin and selected other antibiotics during each of the 6 years of the study period; the susceptibility to isepamicin remained relatively constant over the 6 years of the study period, in contrast with most other antibiotics. Furthermore, the susceptibility to isepamicin was the second highest after carbapenems against Table 3 . Quality control testing. The isepamicin MICs for E. coli ATCC 25922 were always Յ1 mg/liter, similarly to what was described previously (27) . There was categorical agreement in the interpretations of susceptibility to isepamicin between the disk diffusion method and the Vitek 2 system for all of the 20 randomly selected isolates that were tested with the latter method.
DISCUSSION
In our study, isepamicin exhibited very high in vitro activity against the 6,296 unselected clinical Enterobacteriaceae sp. isolates that were collected in a tertiary care university general hospital in Crete, Greece, from 2004 to 2009 from unique patients. Isepamicin was the most active in vitro against all isolates among all of the antibiotics tested, followed by colistin, meropenem, imipenem, and amikacin. High susceptibility to isepamicin was also observed for the subsets of the blood culture isolates and the isolates collected from patients hospitalized in the ICU, in contrast to other antibiotics, such as meropenem. High susceptibility to isepamicin was observed for the carbapenem-nonsusceptible Enterobacteriaceae sp. isolates, the great majority of which were K. pneumoniae isolates. Very high susceptibility to isepamicin was also observed for the Enterobacteriaceae sp. isolates that were nonsusceptible to all of the other aminoglycosides tested. The only exception was Salmonella sp., for which the aminoglycosides are not considered appropriate therapy, even if they appear to be active in vitro, and should not be reported as susceptible according to CLSI guidelines. Resistance to isepamicin did not appear to correlate with
Temporal trend in susceptibilities of the studied Klebsiella pneumoniae isolates to isepamicin, other tested aminoglycosides, and selected other antibiotics during the study period. The horizontal axis refers to the study year, and the vertical axis refers to the percentages of K. pneumoniae isolates that were susceptible to each antibiotic.
resistance to the other aminoglycosides in the K. pneumoniae isolates but was higher for the amikacin-resistant than for the gentamicin-or tobramycin-resistant isolates in, cumulatively, the remaining Enterobacteriaceae spp.
The high susceptibility of the Enterobacteriaceae sp. isolates examined in this study to isepamicin could be explained by the stability of this drug to the action of the most common aminoglycoside-modifying enzymes present in these pathogens. Isepamicin has a profile of resistance to the aminoglycoside-modifying enzymes that is similar to that of amikacin, with the advantage that it is not inactivated by the AAC(6=)-I subfamily of enzymes (32) . The latter enzymes inactivate all of the commonly used aminoglycosides, except gentamicin (37) . The prevalence of AAC(6=)-I enzymes appears to differ by geographical region and can be higher in countries where amikacin is commonly used in clinical practice; Greece appears to be such an example (31) . Other aminoglycoside-modifying enzymes that can be found in Enterobacteriaceae and that inactivate isepamicin include ANT(4=)-II, APH(3=)-VI, and AAC(6=)-III, although their prevalences are rather low (32) . Of these, the ANT(4=)-II enzyme was first found in Pseudomonas aeruginosa but has also been found in Enterobacteriaceae, and the APH(3=)-IV enzyme is found primarily in Acinetobacter baumannii, while the AAC(6=)-III enzyme has been described in specific geographical regions such as Turkey (21, 35, 37) .
In our study, isepamicin exhibited very good in vitro activity specifically against the carbapenem-nonsusceptible K. pneumoniae isolates. The remaining aminoglycosides had poor activity against these pathogens, with gentamicin being the most active, with a susceptibility of 21.4%. In Greece, carbapenem resistance in K. pneumoniae has been related primarily to the production of specific carbapenemases (17, 39) . Since 2002, there has been a polyclonal outbreak of VIM-1 metallo-␤-lactamase-producing K. pneumoniae, which has largely been replaced by KPC-2-producing K. pneumoniae, belonging more often to ST258 (17, 36) . The latter strains first appeared in Crete by late 2007 (18, 30) . ST258 KPC-producing K. pneumoniae strains (7 out of 7) showed susceptibility to isepamicin in another study (27) . Despite the abovedescribed change in the epidemiology of carbapenem-resistant K. pneumoniae in our region, the susceptibility to isepamicin did not substantially change during the 6 years of our study.
Gentamicin has been the most active aminoglycoside against the most of the prevalent carbapenem-resistant and, particularly, the KPC-producing K. pneumoniae clones (10, 25) . This resistance profile is associated with the production of AAC(6=)-I aminoglycoside-modifying enzymes (20, 24) . An aminoglycoside, when active in vitro, could be an effective treatment option for infections with Gram-negative pathogens that are resistant to other aminoglycosides (7). However, isepamicin was inferior to gentamicin when they were both used in combination with ␤-lactams for the treatment of experimental endocarditis caused by AAC(6=)-Ibproducing Enterobacteriaceae (6, 29) . This could be attributed to the low-level resistance to isepamicin conferred by this enzyme (33) . Genes for additional aminoglycoside-modifying enzymes are commonly carried by the resistance plasmids encoding VIM-1 or KPC-2 in K. pneumoniae (10, 20) . This might be an explanation for the low degree of susceptibility to gentamicin observed in our study in comparison with other relevant studies.
Whether isepamicin could constitute an effective treatment option against carbapenemase-producing K. pneumoniae remains to be determined. This might be important considering that the effectiveness and safety profile of the currently available therapeutic options for these pathogens appear to be suboptimal (13) . It should be mentioned that isepamicin has formally been evaluated for clinical use and was approved in this respect in many European countries in the mid-1990s (22, 32) . Several clinical studies agreed that there is no important difference in the clinical effectiveness and safety profile of isepamicin compared with those of amikacin (5). The very high susceptibility to isepamicin of the Enterobacteriaceae sp. isolates collected in our study hospital might relate to the fact that isepamicin was not available for clinical use during the study period. There are differences in the patterns of resistance to aminoglycosides between different regions and in different time periods, which relate mainly to the selection pressure from the use of different members of this class (31) . Nevertheless, the rather limited relevant published data available from different countries (mainly those in which isepamicin was available for clinical use) support the idea that isepamicin has very good in vitro activity against Gram-negative pathogens compared to other commonly used aminoglycosides (12) . The prevalence of resistance to a new aminoglycoside can increase rather quickly, depending on the consumption of the drug (19) . The selection of resistance to isepamicin in Gram-negative bacteria was observed in two Belgian hospitals soon after the institution of isepamicin in the market (38) . Resistance to isepamicin can result from the combination of more than one aminoglycoside-modifying enzyme or of such an enzyme along with decreased permeability or efflux mechanisms (33, 35) . Enterobacteriaceae that carry the NDM metallo-␤-lactamase typically produce 16S rRNA methylases, which inactivate all of the aminoglycosides available for clinical use, including isepamicin (8, 27, 34) .
The findings of our study should be interpreted in the context of potential limitations. The susceptibilities of the included isolates to the antibiotics tested, including isepamicin, were determined by using an automated susceptibility testing system, owing to the retrospective nature of our study. Moreover, interpretative MIC breakpoints of susceptibility of Enterobacteriaceae to isepamicin are not available through the CLSI. Relevant studies, though, have commonly used an MIC breakpoint of susceptibility to isepamicin that matches that to amikacin (1). According to the CLSI, susceptibility to amikacin is defined by an MIC of Յ16 mg/liter. We opted for a more conservative breakpoint of susceptibility to isepamicin according to what was proposed previously by Barry et al. and has been endorsed by CA-SFM (susceptibility defined as an MIC of Յ8 mg/liter) (1).
In conclusion, isepamicin was highly active in vitro against recent clinical Enterobacteriaceae sp. isolates collected at a tertiary care hospital in Greece. Isepamicin was highly active against isolates with resistance to all of the other aminoglycosides tested and against problem pathogens, particularly carbapenem-resistant K. pneumoniae. These findings appear to be promising for a potential role of isepamicin as a last-resort therapeutic option against infections with Enterobacteriaceae that have acquired resistance to commonly used agents. However, the profile of susceptibility of Enterobacteriaceae to isepamicin that was observed in our study needs to be corroborated by additional relevant studies.
